LEXINGTON, Mass., Sept. 4, 2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies 1 , announced today that Jennifer Buell, Ph.D., Chief Communications and External Affairs

- Payment of $4M received for initiation of phase 1 trial - Up to additional $95 million for milestones plus royalties on sales LEXINGTON, Mass., Aug. 15, 2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer

- Cash milestones earned from Merck & Incyte - Three INDs filed and 3 more to be filed during 2018 - CTLA-4 & PD-1 trials treated more than 115 patients; clinical benefit confirmed LEXINGTON, Mass. , Aug. 9, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN ), an immuno-oncology (I-O) company with a

LEXINGTON, Mass., Aug. 2, 2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , will release its second quarter 2018 financial results before the market opens on Thursday,

-- Sunil Gupta, MD, named Vice President Regulatory & Pharmacovigilance -- Anna Wijatyk, MD, named Vice President Clinical Development LEXINGTON, Mass., July 16, 2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with clinical stage checkpoint antibodies, a pipeline of

LEXINGTON, Mass., June 20, 2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1  invites investors and the general public to attend its Annual Meeting of Stockholders to begin

-- Novel discovery improves the immunological activity of certain cancer fighting antibodies -- Agenus' next generation anti-CTLA-4 antibody (AGEN1181) developed using this technology is slated for IND in 2018 LEXINGTON, Mass., June 12, 2018 / PRNewswire / -- A study published in Cancer Cell

LEXINGTON, Mass., June 6 ,  2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , announced today that Jennifer Buell, Ph.D., Chief Communications and External Affairs Officer

- AGEN1884 and AGEN2034 produce clinical benefit 2  in 31% and 42% of patients respectively - Combination trial of AGEN1884 plus AGEN2034 in 2L cervical cancer ongoing to support BLA LEXINGTON, Mass., June 4 ,  2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a

- AGEN1884 (CTLA-4) and AGEN2034 (PD-1) show objective clinical responses - More than 100 patients treated with AGEN1884 and AGEN2034 - Combination trial has commenced in cervical cancer LEXINGTON, Mass., May 17 ,  2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a